Back to top

Image: Bigstock

Here's Why You Should Retain Change Healthcare (CHNG) Stock

Read MoreHide Full Article

Change Healthcare Inc. is well-poised for growth backed by strength in artificial intelligence (AI) and machine learning (ML) efforts and a robust payment accuracy business. However, stiff competition remains a concern.

The stock has soared 96% compared with the industry’s rally of 11.7% in a year’s time. Also, the S&P 500 Index has rose 38.8% in the same time frame.

Change Healthcare — with a market capitalization of $7.25 billion — is an independent healthcare technology platform offering data and analytics-driven solutions to boost clinical financial and patient engagement outcomes in the United States. It anticipates earnings to improve 2% over the next five years. Moreover, the company has a trailing four-quarter earnings surprise 30.4%, on average.

Zacks Investment ResearchImage Source: Zacks Investment Research

Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).

Factor Hurting the Stock

The market for healthcare information technology (HCIT) solutions, devices and services is extremely competitive and rapidly evolving. Consequently, intense competition can put pressure on the company’s pricing and margins.

Key Catalysts

Change Healthcare has been utilizing AI and ML to detect inefficiencies and eliminate them from administrative processes in the healthcare system, thereby lowering costs and help payers, providers, and patients with better outcomes.

Per the fiscal fourth-quarter 2021 earnings call, the company saw increased volumes stemming from new business, sustained growth in its application programming interface (API)-related transaction volumes and from its all payer electronic attachment service. It also witnessed growing traction in new high value-added solutions like its Connected Consumer Health e-commerce suite.

Presently, its marketplace provides around 71 API and software as a service (SaaS) products, offering solutions that aid in revenue cycle management, payments and medical network workflows. During the quarter under review, the company processed approximately 170 million API transactions and is presently processing over 50 million API transactions per month.

During third-quarter fiscal 2021, the company completed the divestiture of its Capacity Management business for $67.5 million. The sale, which is in sync with Change Healthcare’s strategy, will enable the company to focus on the key areas of its business that can deliver the best possible outcomes for customers through the strength of its platform.

Additionally, with respect to Payment Accuracy business, the company is committed toward healthcare plans and payers generating double-digit growth for the same. The company’s end-to-end solution helps drive accuracy early in the payment cycle, thus lowering administrative costs and reducing friction.

Per the fourth-quarter fiscal 2021 earnings call, with respect to its payment accuracy solutions, the company continues to expand its relationships with a wide range of customers, including some of the largest payers in the country and leading healthcare technology providers that are part of its partner community.

Estimates Trend

For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $3.43 billion, indicating an improvement of 10.9% from the year-ago period. The same for adjusted earnings per share stands at $1.59, suggesting growth of 18.7% from the prior-year reported figure.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , DaVita Inc. (DVA - Free Report) and Encompass Health Corporation (EHC - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.

DaVita’s long-term earnings growth rate is estimated at 14.4%.

Encompass Health’s long-term earnings growth rate is projected at 17.3%.

Zacks' Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


DaVita Inc. (DVA) - free report >>

Veeva Systems Inc. (VEEV) - free report >>

Encompass Health Corporation (EHC) - free report >>

Published in